阿格列汀辅助PCI术治疗糖尿病并发冠心病对患者血清APN、MMP-9和TNF-α水平的影响被引量：1

下载PDF

导出

摘要目的：探讨阿格列汀辅助PCI术治疗糖尿病并发冠心病对患者血清APN、MMP-9和TNF-α水平的影响。方法：选取198例糖尿病并发冠心病患者,随机均分为研究组和对照组,两组均给予PCI手术治疗,99例研究组给予阿格列汀药物治疗,99例对照组给予阿托伐他汀药物治疗,比较两组血清APN、MMP-9和TNF-α水平。结果：治疗后两组血清APN水平较治疗前均增高（P〈0.05）且血清MMP-9和TNF-α水平降低（P〈0.05）;治疗后研究组较对照组血清APN水平增高（P〈0.05）且MMP-9和TNF-α水平降低（P〈0.05）。结论：阿格列汀辅助PCI术治疗糖尿病并发冠心病能有效的升高血清APN水平和降低血清MMP-9和TNF-α水平。

作者刘震吴巧娟王维娜卢燕毕婷婷

机构地区张家口市第一医院张家口市妇幼保健院

出处《医疗装备》 2016年第2期30-31,共2页 Medical Equipment

关键词糖尿病冠心病阿格列汀 PCI术

分类号 R587.1 [医药卫生—内分泌] R541.4 [医药卫生—内科学]

引文网络
相关文献

参考文献6

1云冬晔,白晓光.2型糖尿病并发冠心病发病机制及治疗[J].中国社区医师（医学专业）,2012,14(12):165-166. 被引量：8
2Baetta R, Corsini A. Pharmacology of dipeptidyl peptidase - 4 inhibi- tors [J] .Drugs, 2011, 71 (11): 1441-1467. 被引量：1
3王瑜,胡明,占美,代国友,程艳霞,苏娜,方煜.阿格列汀治疗2型糖尿病的系统评价[J].中国医院药学杂志,2014,34(23):2014-2022. 被引量：18
4张会利.阿托伐他汀对糖尿病合并冠心病患者血脂和心脏功能的影响[J].中西医结合心血管病电子杂志,2015,3(2):40-41. 被引量：13
5刘俏,李曦铭,丛洪良,侯凯,马洪俊.冠心病伴2型糖尿病患者PCI治疗后他汀类药物服用时程与其不良事件的相关分析[J].中国临床研究,2015,28(2):163-166. 被引量：16
6郑文成..强化他汀在PCI干预的冠心病患者的疗效观察及其对APN、MMP-9和TNF-α的影响[D].河北医科大学,2012:

二级参考文献48

1Danaei G, Finucane M M, Lu Yuan, et al. National, region- al, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examina- tion surveys and epidemiological studies with 370 country-years and 2 7 million participants[J]. The Lancet, 2011, 378 (9785) : 31-40. 被引量：1
2Consultation W H O. Definition, diagnosis and classification of diabetes mellitus and its complications[M]. Geneva, 1999. 被引量：1
3Mathers C D, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030[J]. PLoS Medicine, 2006, 3(11): e442. 被引量：1
4DeFronzo R A, Fleck P. R, Wilson C A, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in pa- tients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study[J]. Dia- betes Care, 2008, 3l(12) :2315-2317. 被引量：1
5Nauck M A, Ellis G C, Fleck P R, et al. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to met- formin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, ran- domised, double-blind, placebo-controlled study[J]. Int J Clin Pract, 2009, 63(1): 46-55. 被引量：1
6Pratley R E, ipnes M S, Fleck P R, etal. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy[J]. Diabetes Obes Metab, 2009, 11(2): 167-176. 被引量：1
7Pratley R E, Reusch J E B, Fleck P R, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study[J]. Current Medical Research and Opinion, 2009, 25(10) : 2361-2371. 被引量：1
8Rosenstock J, Inzucchi S E, Seufert J, et al. Initial combina- tion therapy with alogliptin and pioglitazone in drug naive pa- tients with type 2 diabetes [J]. Diabetes Care, 2009, 33(11): 2406-2408. 被引量：1
9Rosenstock J, Rendell M S, Gross J L, etal. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA (1C) without causing weight gain or increased hypoglycaemia [J]. Diabetes Obes Metab, 2010, 11(12): 1145-1152. 被引量：1
10Kaku K, Itayasu T, Hiroi S, etal. Efficacy and safety of alo- gliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study [J]. Diabetes Obes Metab, 2011, 13(11): 1028-1035. 被引量：1